atl 1102 for DMD could be a Coy maker., page-74

When Sarepta announced that their trial drug Golodirsen for DMD was effective its market cap increased by $400 mill... To $2.41 billion.
The DMD market for Sarepta is $1 billion.
One has to understand that Atl 1102 is going to be first to market because its target is inflammation in DMD patients.Very different to Sareptas drugs....Anp 's market is going to be in excess of $2 billion if the data generated shows effiency...I'm sure Sarepta will be watching with great interest...Even ITSAGAS is eager for some good news....$$$